'Paxlovid reduces the risk of deaths in high-risk groups'
By Jung, Sae-Im | translator Kim, Jung-Ju
23.07.24 18:02:56
가나다라
0
Pfizer Korea holds a press conference to celebrate the official approval of Paxlovid
“Used to prevent severe disease, not to treat symptoms.... patients with high-risk factors should use Paxlovid”
May be switched to a private system in 2H...”is currently discussing reimbursement listing with the health authorities”
‘Paxlovid,’ the oral COVID-19 treatment used to prevent progression to severe COVID-19, has finally removed its ‘temporary’ approval tag, 1 year and 7 months after its introduction to Korea. Although the drug has now been officially approved as a new drug, it is still not being well utilized on-site. Therefore, whether the misunderstandings and misconceptions regarding the drug can be cleared and be actively prescribed to patients by HCPs is gaining attention.
The Ministry of Food and Drug Safety officially approved Pfizer’s COVID-19 treatment ‘Paxlovid (nirmatrelvir ritonavir tablets)’ on the 14th. The approval comes 1 year and 7 months after the company had received the emergency use approval (EUA
Jung, Sae-Im (same@dailypharm.com)
If you want to see the full article, please JOIN US (click)